Overview
This study will explore whether tirzepatide is a practical and acceptable treatment for postmenopausal females with a history of hormone receptor-positive breast cancer and obesity. The investigators aim to understand whether participants are willing and able to take this medication once weekly for 6 months and whether it may help improve weight and overall health. There will be monthly check-ins to monitor progress and safety. At the beginning and end of the study, participants will undergo body composition assessments, blood tests and a stool sample will be collected, and surveys will be completed.
Eligibility
Inclusion Criteria:
- Biologically female
- Age ≥ 18
- Obesity as defined by current BMI ≥ 30 kg/m²
- Postmenopausal as defined by one or more of the following
- Age ≥60 years
- Age \<60 years with amenorrhea for ≥ 1 year
- Documented bilateral surgical oophorectomy
- Chemical menopause with the addition of LHRH agonists at least 12 weeks prior to enrolment, and plan to remain on LHRH agonists throughout the trial
- HR+ (ER and/or PR) stage 0-III breast cancer
- Completed curative treatment (surgery, chemotherapy, radiotherapy) at least 12 weeks prior to enrolment
- Insurance approval for tirzepatide or willing to pay out of pocket
- Willing to provide informed consent and comply with study procedures
Exclusion Criteria:
- Stage IV breast cancer
- Concomitant use of CDK inhibitors
- Concomitant use of antiHER2 therapy
- The PI may be consulted regarding enrollment of females receiving other endocrine therapy medications
- Other active malignancy requiring treatment
- Enrollment in another investigational clinical trial
- Contraindication to tirzepatide
- Treatment with a GLP-1 receptor agonist within the last 3 months
- Diabetes requiring insulin
- Any disorder, unwillingness, or inability, not covered by any of the other exclusion criteria, which in the investigator's opinion, might jeopardize the subject's safety or compliance with the protocol
